Home > Insider Trading > Filing (0001209191-23-018545)

Filing Details

Accession Number:: 0001209191-23-018545
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-14 17:16:58
Reporting Period:: 2023-03-06

Accepted Time:: 2023-03-14 17:16:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1000694	Novavax Inc	NVAX	Biological Products, (No Disgnostic Substances) (2836)	222816046

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1342823	M Gregory Glenn	C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878	President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-06	3,000	$7.48	11,473	No	4	P	Direct
Common Stock	Acquisiton	2023-03-07	2,000	$7.04	13,473	No	4	P	Direct
Common Stock	Acquisiton	2023-03-10	1,000	$6.50	14,473	No	4	P	Direct
Common Stock	Acquisiton	2023-03-10	6,298	$6.52	20,771	No	4	M	Direct
Common Stock	Disposition	2023-03-10	2,432	$6.52	18,339	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-03-10	6,298	$0.00	6,298	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,596			No	4	M	Direct

Footnotes

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
Each RSU represents a contingent right to receive one share of the Company common stock.
The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.